Clinical trial

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

NCT02358473

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention mogamulizumab Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-01-01

PhasePHASE1

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

mogamulizumabBIOLOGICAL

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

Kyowa Kirin, Inc.lead sponsor

Mapped research locations

HoustonTexas, United States1 BaltimoreMaryland, United States1 San AntonioTexas, United States1 CantonOhio, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02358473 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.